InvestorsHub Logo

misiu143

02/21/17 8:36 AM

#11149 RE: goldenisla #11148

Some think that IV injections every 2 weeks for entire life is so easy , well it is not , sometimes after one or two years it is difficult to find a vein.
SC is much better , patients self injecting , and once a week is really not bad . Some patients need to inject Insulin SC couple times a day for entire life.

Also patients who are responding to Pro 140 developed much lower Viral load.
Statistics from couple months ago show , they have 36% patients with viral load below 50 copies/mill , just look what % with Pro 140 is below 1 copy/mill

And BTW they also had 30 patients for P3 IV adjunct study.

According to Dr Chen they not planning monotherapy. If ever they will change , we talking many years from now to finish.

But yes , I believe that some patients will benefits from either treatment , but I don"t believe they are a big competition to Pro 140.




gestalt2

02/21/17 10:28 AM

#11155 RE: goldenisla #11148

I seem to remember that Tai Med is partially invested in by the Chinese government and is a Hong Kong registered company. Not sure if that means anything but wouldn't that make it difficult to partner or buy-out by a BP? I honestly don't know - i'm just thinking CYDY might be a much more available acquisition than Tai Med to BP.